PROLOR Biotech
Weizmann Science Park
3 Sapir Street
Nes Ziona
74140
Tel: 866-644-7811
Fax: 972-8-9300091
89 articles about PROLOR Biotech
-
Opko Health, Inc. Announces Dismissal Of PROLOR Biotech Class Action Lawsuit
5/8/2014
-
Opko Health, Inc. Completes Acquisition of PROLOR Biotech
8/29/2013
-
PROLOR Biotech to Present Positive Results From Preclinical Studies of Long-Acting Clotting Factor VIIa-CTP at ISTH 2013
7/3/2013
-
PROLOR Biotech to Present New Data on its Long-Acting Human Growth Hormone and Long-Acting Oxyntomodulin at ENDO 2013
6/13/2013
-
PROLOR Biotech Initiates Pivotal Phase III Trial Of Its Longer-Acting Version Of Human Growth Hormone
6/4/2013
-
PROLOR Biotech to Present at Jefferies and Co. 2013 Global Healthcare Conference
5/31/2013
-
Opko Health, Inc. Acquires PROLOR Biotech for $480 Million
4/24/2013
-
PROLOR Biotech Receives Notice of Allowance For New U.S. Patent Covering Long-Acting Coagulation Factors VII and IX
4/8/2013
-
PROLOR Biotech Receives Notice of Allowance for New U.S. Patent Covering Methods for Decreasing Body Fat With hGH-CTP
3/5/2013
-
PROLOR Biotech's Longer-Acting Human Growth Hormone Receives Orphan Drug Designation in Europe
2/13/2013
-
PROLOR Biotech to Present New Preclinical Data on Its Long-Acting Clotting Factor VIIa at Leading European Scientific Conference
2/6/2013
-
PROLOR Biotech Receives Notice of Allowance for New U.S. Patent Covering Broad Applications of its CTP Platform for Long Acting Therapeutic Proteins
1/7/2013
-
PROLOR Biotech to Present at Oppenheimer 23rd Annual Healthcare Conference
12/10/2012
-
PROLOR Biotech to Present Preclinical Data on Its Long-Acting Clotting Factor Vlla at 2012 American Society of Hematology Annual Meeting
12/7/2012
-
New Patent Covering PROLOR Biotech's Reversible-Pegylation Platform Technology is Allowed by U.S. Patent Office
11/13/2012
-
PROLOR Biotech to Present Data on Its Long-Acting Human Growth Hormone at Congress of the GRS and IGF Society
10/18/2012
-
PROLOR Biotech Announces Positive Results From Preclinical Toxicology Study of Its Reversible-Pegylation Platform Technology
10/16/2012
-
PROLOR Biotech Receives Notice of Allowance for New U.S. Patent for Its Long-Acting Human Growth Hormone
10/3/2012
-
PROLOR Biotech to Present Data on Its Long-Acting Human Growth Hormone at Pediatric Endocrinology Meeting
9/21/2012
-
PROLOR Biotech to Present Data on Its Long-Acting Human Growth Hormone at International NeuroEndocrine Meeting
9/13/2012